You are here

  • Home
  • Archive
  • Volume 72, Issue Suppl 3
  • FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the planetas study

Citation Tools

Article menu
Download PDFPDF
Poster Presentation
Spondyloarthritis - treatment
FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the planetas study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Park W, Jaworski J, Brzezicki J, et al
FRI0421 A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of ct-p13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the planetas study
Annals of the Rheumatic Diseases 2013;72:A516-A517.